A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This early-phase (Phase 1) study is testing a new experimental drug called CTIM-76 in people whose ovarian, testicular, or endometrial cancer has come back or is not responding to standard treatments. The drug targets a protein called CLDN6 found on some cancer cells. The main goal is to find out if the drug is safe and what dose works best. **You may be eligible if...** - You have ovarian cancer that has returned or stopped responding to platinum-based chemotherapy, or advanced testicular or endometrial cancer - Your tumor tests positive for the CLDN6 protein - Your cancer can be measured on imaging scans - You are well enough to carry out daily activities (ECOG 0–2) and have a life expectancy of at least 12 weeks - Your liver, kidneys, and blood counts are in acceptable range **You may NOT be eligible if...** - Cancer has spread to your brain or spinal fluid - You have an active, uncontrolled infection or a serious medical condition that would make participation unsafe - You are already taking part in another clinical trial Talk to your doctor to see if this trial is right for you.